This conference represents a Joint Meeting and Exhibition ASCO meeting in the Kingdom of Saudi Arabia and I am truly amazed at the progress we have made in this medical field by standard of care that helps us take better care of our oncology patients in Saudi Arabia. The respective chairs for both Scientific and Organizing Committees have worked diligently in spite of the rise of a global pandemic that hit the world by storm but members forming these committees and staff managed to organize such an important event for this year.
The ASCO mission in the kingdom is to defeat cancer through research and education promoting the highest quality patient care possible. We envision our country where cancer is prevented or cured and that every survivor is healthy and fit. As a Chairman this year, I have had the opportunity to observe firsthand the various things ASCO does all over the world to make a difference in cancer care and I cannot wait to share them over the next few days.
Annual meeting attendees in the kingdom will continue to find the sophisticated scientific presentations and comprehensive educational content that they expect and will also see some variations to the Meeting program taking better care to all our patients with cancer is our ultimate goal. I personally guarantee that your attendance in this November’s Annual Meeting will help make a difference in cancer care.
Thanks for attending and for your participation and if we both get the chance, I am looking forward to meet with you personally at the venue.
Abdullah Al-Sharm, MD
Chairman, ASCO Riyadh, Saudi Arabia
ABOUT THE EVENT
The Joint Best of ASCO® 2021 meeting & exhibation is the most important educational platform in the region for Oncology, Hematology and Radiation Oncology . In addition to health promotion related to these domains.
Hematology, Medical Oncology, Internal Medicine, Radiation Oncology, Pediatric Oncology, Oncology and Palliative Care Nursing
All healthcare professionals invited to attend this event as an annual gathering connects with other stakeholders from all specialties
Share up-to-date best practices in Oncology, Hematology and Radiation Oncology and other relevant disciplines and transfer experiences and enhance knowledge
EXECUTIVE BOARD MEMBERS
Best of ASCO® 2021
CHAIRMEN and Speakers
Best of ASCO® 2021
Welcome to the dedicated to building remarkable Schedule!
"Breast Cancer Index (BCI) and Prediction of Benefit from Extended Aromatase Inhibitor (AI) Therapy (tx) in HR+ Breast Cancer: NRG Oncology/NSABP B-42. Trastuzumab Plus Endocrine Therapy or Chemotherapy as first-line Treatment for Metastatic Breast Cancer with Hormone Receptor-Positive and HER2-positive: The Sysucc-002 Randomized Clinical Trial. "
Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890).